Analysts expect Akorn, Inc. (NASDAQ:AKRX) to post sales of $252.74 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Akorn’s earnings, with estimates ranging from $243.20 million to $260.83 million. Akorn posted sales of $280.73 million in the same quarter last year, which suggests a negative year over year growth rate of 10%. The business is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Akorn will report full-year sales of $252.74 million for the current year, with estimates ranging from $905.00 million to $1.06 billion. For the next fiscal year, analysts forecast that the company will report sales of $1.07 billion per share, with estimates ranging from $1.00 billion to $1.15 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Akorn.

A number of research firms have issued reports on AKRX. Piper Jaffray Companies restated a “hold” rating and issued a $34.00 target price on shares of Akorn in a report on Thursday. TheStreet lowered shares of Akorn from a “b-” rating to a “c” rating in a report on Tuesday, August 1st. BidaskClub lowered shares of Akorn from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Royal Bank Of Canada set a $34.00 target price on shares of Akorn and gave the company a “hold” rating in a report on Sunday, July 30th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $34.00 target price on shares of Akorn in a report on Wednesday, July 19th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. Akorn presently has an average rating of “Hold” and an average price target of $28.56.

Akorn (NASDAQ AKRX) traded down 0.03% during trading on Friday, hitting $33.31. 1,781,794 shares of the stock traded hands. The company’s 50 day moving average price is $33.54 and its 200-day moving average price is $29.05. The stock has a market cap of $4.16 billion, a P/E ratio of 33.65 and a beta of 1.36. Akorn has a 52-week low of $17.61 and a 52-week high of $34.00.

In other news, COO Bruce Kutinsky sold 40,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $33.46, for a total transaction of $1,338,400.00. Following the completion of the transaction, the chief operating officer now owns 317,480 shares of the company’s stock, valued at approximately $10,622,880.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Brian Tambi sold 5,165 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $33.37, for a total transaction of $172,356.05. The disclosure for this sale can be found here. Corporate insiders own 28.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of AKRX. State Treasurer State of Michigan increased its position in Akorn by 0.3% in the first quarter. State Treasurer State of Michigan now owns 35,400 shares of the company’s stock worth $852,000 after buying an additional 100 shares in the last quarter. Public Employees Retirement Association of Colorado increased its position in Akorn by 0.8% in the second quarter. Public Employees Retirement Association of Colorado now owns 19,534 shares of the company’s stock worth $655,000 after buying an additional 158 shares in the last quarter. Pacer Advisors Inc. increased its position in Akorn by 1.4% in the second quarter. Pacer Advisors Inc. now owns 12,889 shares of the company’s stock worth $432,000 after buying an additional 180 shares in the last quarter. Mason Street Advisors LLC increased its position in Akorn by 0.6% in the first quarter. Mason Street Advisors LLC now owns 41,143 shares of the company’s stock worth $991,000 after buying an additional 226 shares in the last quarter. Finally, Advantus Capital Management Inc increased its position in Akorn by 2.3% in the first quarter. Advantus Capital Management Inc now owns 11,151 shares of the company’s stock worth $269,000 after buying an additional 256 shares in the last quarter. 74.73% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/252-74-million-in-sales-expected-for-akorn-inc-nasdaqakrx-this-quarter/1478836.html.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Get a free copy of the Zacks research report on Akorn (AKRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.